Longevity Next

Biomarker

Composite Aging Biomarker Panel

Source-reviewed Last reviewed: 2026-07-06
LN Evidence Score 3 of 5
LN Claim Risk Score 3 of 5
LN Commercial Maturity Score 2 of 5
LN Clinic Transparency Score 0 of 5

Summary

Research-stage biomarker category covering DNA methylation age and pace-of-aging measures. The source packet supports age-prediction, biomarker-development, and observational association context; it does not establish stand-alone diagnosis, clinical utility, or intervention-response guidance.

Intelligence Take

Useful for evidence mapping when limits are explicit. Composite aging biomarkers can help organize risk and research discussions, but the current source packet does not show that an individual score should guide care or that changing a score changes health outcomes.

Evidence Basis

Source packet maps this record to peer-reviewed DNA methylation age, DNAm PhenoAge, DunedinPACE, and DunedinPoAm papers. Evidence stage: biomarker development, validation, and observational association with health-related outcomes; not consumer clinical-utility proof.

Limitations

Do not describe these measures as a definitive reading of a person's biological age. Association, validation, modifiability, clinical utility, and commercial interpretation are separate questions. No personalized testing, treatment, or product recommendation is implied.

Source-reviewed. This record summarizes biomarker source context for editorially reviewed public reference. It is not medical advice and should not be used for diagnosis, individual interpretation, product selection, or treatment decisions.